The preliminary will survey the security of INM-755 as well as its underlying adequacy to treat side effects and recuperate wounds north of 28 days. InMed Drugs has enroled the initial juvenile subject into the Stage II 755-201-EB preliminary of its investigational drug, INM-755 cannabinol (CBN) cream, to treat epidermolysis bullosa (EB) patients. Likewise, the preliminary had closed treatment...